These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 19129538)

  • 1. Elimination of antibodies to recombinant enzyme in Pompe's disease.
    Mendelsohn NJ; Messinger YH; Rosenberg AS; Kishnani PS
    N Engl J Med; 2009 Jan; 360(2):194-5. PubMed ID: 19129538
    [No Abstract]   [Full Text] [Related]  

  • 2. Enzyme replacement therapy in late-onset Pompe's disease: a three-year follow-up.
    Winkel LP; Van den Hout JM; Kamphoven JH; Disseldorp JA; Remmerswaal M; Arts WF; Loonen MC; Vulto AG; Van Doorn PA; De Jong G; Hop W; Smit GP; Shapira SK; Boer MA; van Diggelen OP; Reuser AJ; Van der Ploeg AT
    Ann Neurol; 2004 Apr; 55(4):495-502. PubMed ID: 15048888
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized study of alglucosidase alfa in late-onset Pompe's disease.
    van der Ploeg AT; Clemens PR; Corzo D; Escolar DM; Florence J; Groeneveld GJ; Herson S; Kishnani PS; Laforet P; Lake SL; Lange DJ; Leshner RT; Mayhew JE; Morgan C; Nozaki K; Park DJ; Pestronk A; Rosenbloom B; Skrinar A; van Capelle CI; van der Beek NA; Wasserstein M; Zivkovic SA
    N Engl J Med; 2010 Apr; 362(15):1396-406. PubMed ID: 20393176
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Morphological changes in muscle tissue of patients with infantile Pompe's disease receiving enzyme replacement therapy.
    Winkel LP; Kamphoven JH; van den Hout HJ; Severijnen LA; van Doorn PA; Reuser AJ; van der Ploeg AT
    Muscle Nerve; 2003 Jun; 27(6):743-51. PubMed ID: 12766987
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Pompe's disease: the role for early diagnosis and treatment].
    Cerini E; Bini M; Donati A; Andaloro L; Compagnoni G
    Pediatr Med Chir; 2007; 29(5):270-2. PubMed ID: 18402397
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pompe's disease].
    Laforêt P
    Rev Med Interne; 2007 Dec; 28 Suppl 4():S290-1. PubMed ID: 18029059
    [No Abstract]   [Full Text] [Related]  

  • 7. Late-onset Pompe's disease.
    Teener JW
    Semin Neurol; 2012 Nov; 32(5):506-11. PubMed ID: 23677658
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Enzyme replacement therapy in Pompe's disease].
    Merk T; Wibmer T; Schumann C; Krüger S
    Med Klin (Munich); 2007 Jul; 102(7):570-3. PubMed ID: 17634875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Pompe's disease. Part II. Treatment strategies and enzyme replacement].
    Illés Z; Várdi Visy K
    Ideggyogy Sz; 2009 Sep; 62(9-10):299-307. PubMed ID: 19835271
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glycogen storage disease type II (Pompe's disease): the first biochemical evidence in Thailand.
    Rangdaeng S; Scollard DM; Srichairatanakol S; Sutthachit M; Phornphutkul C
    J Med Assoc Thai; 1987 Sep; 70(9):536-42. PubMed ID: 2960768
    [No Abstract]   [Full Text] [Related]  

  • 11. Nephrotic syndrome complicating alpha-glucosidase replacement therapy for Pompe disease.
    Hunley TE; Corzo D; Dudek M; Kishnani P; Amalfitano A; Chen YT; Richards SM; Phillips JA; Fogo AB; Tiller GE
    Pediatrics; 2004 Oct; 114(4):e532-5. PubMed ID: 15466083
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral administration of recombinant human acid α-glucosidase reduces specific antibody formation against enzyme in mouse.
    Ohashi T; Iizuka S; Shimada Y; Eto Y; Ida H; Hachimura S; Kobayashi H
    Mol Genet Metab; 2011 May; 103(1):98-100. PubMed ID: 21320791
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monitoring cardiac function by B-type natriuretic peptide (BNP) in patients with infantile Pompe's disease treated with recombinant alpha-glucosidase.
    Hahn A; Schmidt D; Hagel KJ; Neubauer BA; Katz N
    Clin Lab; 2006; 52(11-12):615-9. PubMed ID: 17175893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pompe's disease or glycogen storage disease].
    Vanto T; Salmi TT; Kalimo H; Lang H; Näntö V; Berlin M; Penttinen R
    Duodecim; 1982; 98(9):709-16. PubMed ID: 7049663
    [No Abstract]   [Full Text] [Related]  

  • 15. alpha-glucosidase (CHO) (Genzyme).
    Lachmann RH
    Curr Opin Investig Drugs; 2004 Oct; 5(10):1101-10. PubMed ID: 15535432
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune modulation in Pompe disease treated with enzyme replacement therapy.
    Banugaria SG; Patel TT; Kishnani PS
    Expert Rev Clin Immunol; 2012 Aug; 8(6):497-9. PubMed ID: 22992140
    [No Abstract]   [Full Text] [Related]  

  • 17. Pompe's disease.
    van der Ploeg AT; Reuser AJ
    Lancet; 2008 Oct; 372(9646):1342-53. PubMed ID: 18929906
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enzyme replacement in Pompe disease with an alpha-glucosidase-low density lipoprotein complex.
    Williams JC; Murray AK
    Birth Defects Orig Artic Ser; 1980; 16(1):415-23. PubMed ID: 7004520
    [No Abstract]   [Full Text] [Related]  

  • 19. Use of immobilized antibodies in investigating acid alpha-glucosidase in urine in relation to Pompe's disease.
    Schram AW; Brouwer-Kelder B; Donker-Koopman WE; Loonen C; Hamers MN; Tager JM
    Biochim Biophys Acta; 1979 Apr; 567(2):370-83. PubMed ID: 36157
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enzyme replacement therapy in severe adult-onset glycogen storage disease type II.
    Ravaglia S; Danesino C; Pichiecchio A; Repetto A; Poloni GU; Rossi M; Fratino P; Moglia A; Costa A
    Adv Ther; 2008 Aug; 25(8):820-9. PubMed ID: 18704279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.